C5 and paroxysmal nocturnal hemoglobinuria: In May 2021, pegcetacoplan was approved by the US FDA to treat adults with paroxysmal nocturnal hemoglobinuria (PNH), and it is the first to target C3, a complement component upstream of C5 [40].